Eris Lifesciences Ltd Share Price

WATCH OUT FOR CORPORATE ACTIONS

Watch out for the Corporate actions today 29-May-2026 on the below mentioned stocks: - Life Insurance Corporation of India (LIC) : - Life Insurance Corporation of India 1:1 Bonus Issue (Investors receive 1 free additional share for every 1 share held). The Ex-Date and Record Date are both fixed for May 29, 2026. Bajaj Auto Ltd, GlaxoSmithKline Pharma, Torrent Pharmaceuticals, ERIS Lifesciences Ltd, ICICI Lombard GI, Home First Finance, and Bank of India will trade Ex-Dividend tomorrow the 29-May-2026.

Earnings Alert: Stocks in Focus Ahead of Q4 Announcements

📊 Q4 Results Watch | Earnings Announcement Today Investors and market participants will closely track Q4 earnings today from: •

Swing Bullish Strategy – Eagle Momentum (Weekly)

Swing Bullish Strategy – Eagle Momentum (Weekly)

Eris Lifesciences Receives HALMED Inspection Findings; Minimal Operational Impact Expected

Eris Lifesciences has received inspection findings from Croatia's HALMED agency following a March 9–13, 2026 audit of its two Ahmedabad manufacturing units: Unit 1 (general liquid/dry powder injectables) and Unit 2 (betalactam dry powder injectables). The inspection identified procedural non-compliance observations requiring alignment with EU GMP standards under Directive 2017/1572. Eris is preparing its response and Corrective and Preventive Actions (CAPAs) for submission to HALMED. Operational Impact: Existing business: Expected to remain largely unaffected. European CDMO pipeline: Commercialization timelines may see delays pending remediation and re-approval. The company has committed to implementing necessary improvements and will request a follow-up inspection once corrective measures are complete to reinstate regulatory approvals for both facilities. While the findings underscore the rigorous scrutiny of EU-linked regulators, Eris's proactive remediation approach and strong domestic footprint should cushion near-term impact. The episode highlights the ongoing compliance challenges for Indian pharma exporters in regulated markets, but management's assurance of minimal disruption reinforces confidence in the company's quality systems and operational resilience.

Eris Lifesciences Ltd.

Launch of Weekly Shot of Semaglutide - ERIS Lifesciences Ltd

Code BSE: 540596 NSE: